<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">M. Fathi Ilmawan</style></author><author><style face="normal" font="default" size="100%">Soetjipto</style></author><author><style face="normal" font="default" size="100%">M. Guritno Suryokusumo</style></author><author><style face="normal" font="default" size="100%">M. Miftahussurur</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Effects of Hyperbaric Oxygen Therapy on the Expression of FGF, MMP-9 and Occludin in the Repair of Gastric Mucosal Erosions</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">FGF</style></keyword><keyword><style  face="normal" font="default" size="100%">Gastric mucosal erosions</style></keyword><keyword><style  face="normal" font="default" size="100%">HBOT</style></keyword><keyword><style  face="normal" font="default" size="100%">MMP-9</style></keyword><keyword><style  face="normal" font="default" size="100%">Occludin.</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">June 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">660-671</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;This study was conducted to evaluate the immunohistochemical (IHC) expression of fibroblast growth factor (FGF), matrix metalloproteinase-9 (MMP-9) and occludin in the repair of gastric mucosal erosions in Wistar rats was induced by administration of aspirin, one of the non-steroidal anti-inflammatory drugs (NSAIDs). These expressions are associated with changes in histopathological features. This experimental research used a posttest only control group design. The research sample was 28 male Wistar rats that met the inclusion criteria, but not met the exclusion criteria. The samples were randomly allocated into four groups. Group 1 as negative control and group 2 as positive control. Group 3 as treatment 1, which was given HBOT (hyperbaric oxygen therapy) 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Group 4 as treatment 2, which was given HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 10 days, after aspirin induction at 30 mg/kgBW/day for 10 days. Each group was evaluated the immunohistochemical (IHC) expression of FGF, MMP-9 and occludin, using the Remmele scale index, immune reactive score (IRS). The expressions were correlated with histopathological changes, using the HAI (Histology Activity Index) method. The results show that the HBOT 2.4 ATA for 3 x 30 minutes/day (air break 5 minutes) for 5 days and for 10 days, it can improve FGF (p=0.016) and occludin (p=0.021) expression significantly. The HBOT can also reduce inflammation (p=0.005), epithelial defects (p&amp;lt;0.001) and MMP-9 expression (0.042). There is a significant difference in occludin expression (p=0.034) between 5-day HBOT and 10-day HBOT. However, there was no significant difference between the 5-day HBOT and the 10-day HBOT for reduce inflammation (p=0.845), epithelial defects (p=0.469), FGF expression (0.054) and MMP-9 expression (0.470). The provision of HBOT at 2.4 ATA significantly improved gastric mucosal erosion in NSAID-induced gastric mucosal erosion Wistar rats model, by decreasing MMP-9 expression, as well as increasing FGF and occludin expression. There is a significant difference in occludin expression between 5-day HBOT and 10-day HBOT.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><accession-num><style face="normal" font="default" size="100%">25</style></accession-num><section><style face="normal" font="default" size="100%">660</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;M. Fathi Ilmawan&lt;sup&gt;1,2&lt;/sup&gt;, Soetjipto&lt;sup&gt;3,*&lt;/sup&gt;, M. Guritno Suryokusumo&lt;sup&gt;4&lt;/sup&gt;, M. Miftahussurur&lt;sup&gt;5&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Sciences, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Internal Medicine, Faculty of Medicine, Universitas Hang Tuah, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Universitas Airlangga Hospital, Surabaya; Institute of Tropical Disease, Department of Medical Biochemistry, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Hyperbaric, Universitas Pembangunan Nasional, Jakarta, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Universitas Airlangga Hospital, Surabaya; Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maulana Farid Rizki</style></author><author><style face="normal" font="default" size="100%">Paulus Sugianto</style></author><author><style face="normal" font="default" size="100%">Margarita Maria Maramis</style></author><author><style face="normal" font="default" size="100%">Soetjipto</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Viral Meningoencephalitis Patient with Comorbid Major Depression with Psychotic Symptoms: A Case Report</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Comorbid</style></keyword><keyword><style  face="normal" font="default" size="100%">Depression</style></keyword><keyword><style  face="normal" font="default" size="100%">Viral meningoencephalitis</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">455-458</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Viral meningoencephalitis causes meninges and brain parenchyma inflammation, thus provoking significant morbidity and mortality. Clinical features include neurological and psychiatric symptoms depending on the brain involved, mild symptoms such as fever, headache, neck stiffness, and confusion, or severe symptoms such as seizures, weakness, hallucinations, and coma. Therefore, the clinical diagnosis and treatment of such cases are challenging to make. This case report describes an adult male patient suffering from viral meningoencephalitis with comorbid major depression with psychotic symptoms. The patient requires holistic management of meningoencephalitis with comorbid depression and neuropsychiatric symptoms that may occur in the long term.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Case Report</style></work-type><accession-num><style face="normal" font="default" size="100%">29</style></accession-num><section><style face="normal" font="default" size="100%">455</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Maulana Farid Rizki&lt;sup&gt;1&lt;/sup&gt;, Paulus Sugianto&lt;sup&gt;2,*&lt;/sup&gt;, Margarita Maria Maramis&lt;sup&gt;3&lt;/sup&gt;, Soetjipto&lt;sup&gt;3&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Resident, Department of Neurology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Medical Staff, Department of Neurology, Faculty of Medicine, Airlangga University, Dr. Soetomo General Hospital, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Medical Staff, Department of Psychiatry, Faculty of Medicine, Airlangga University, Dr. Soetomo General Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>